Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1997-12

AUTHORS

Harvey I. Pass, Barbara K. Temeck, Karen Kranda, Gunther Thomas, Angelo Russo, Paul Smith, Walt Friauf, Seth M. Steinberg

ABSTRACT

Background: Patients with malignant pleural mesothelioma (MPM) usually die of progressive local disease. This report describes the results of a Phase III trial comparing maximum debulking surgery and postoperative cisplatin, interferon α-2b, and tamoxifen (CIT) immunochemotherapy with and without intraoperative photodynamic therapy (PDT) to determine (1) whether such a multimodal approach can be performed with minimum morbidity and mortality in malignant pleural mesothelioma (MPM), and (2) whether first-generation (i.e., 630-nm laser light, Photofrin II) intrapleural PDT impacts on local recurrence or survival.Methods: From July 1993 to June 1996, 63 patients with localized MPM were randomized to either PDT or no PDT. The tumors of 15 patients could not be debulked to 5 mm. Patients assigned to PDT (n=25) and no PDT (n=23) were similar with respect to age, sex, tumor volume, and histology.Results: The type of resection (11 pleurectomies and 14 pneumonectomies vs. 12 pleurectomies and 11 pneumonectomies), length postoperative stay, and ICU time were comparable (PDT vs. no PDT). There was one operative death (hemorrhage), and each group had two bronchopleural fistulas. Postoperative staging divided patients into the following categories: stage I: PDT, 2, no PDT, 2; stage II: PDT, 2, no PDT, 2; stage III, PDT, 21; no PDT, 17; stage IV, PDT, 0; 0; no PDT, 2. Comparable numbers of CIT cycles were delivered. Median survival for the 15 non-debulked patients was 7.2 months, compared to 14 months for the 48 patients on protocol. There were no differences in median survival (14.4 vs. 14.1 months) or median progression-free time (8.5 vs. 7.7 months), and sites of first recurrence were similar.Conclusions: Aggressive multimodal therapy can be delivered for patients with higher stage MPM. First-generation PDT does not prolong survival or increase local control for MPM. More... »

PAGES

628-633

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf02303746

DOI

http://dx.doi.org/10.1007/bf02303746

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1051247127

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/9416409


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon alpha-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon-alpha", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Intraoperative Care", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mesothelioma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Photochemotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pleural Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recombinant Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tamoxifen", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "From the Thoracic Oncology Section, National Institutes of Health, Bethesda, Maryland, USA", 
          "id": "http://www.grid.ac/institutes/grid.94365.3d", 
          "name": [
            "From the Thoracic Oncology Section, National Institutes of Health, Bethesda, Maryland, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pass", 
        "givenName": "Harvey I.", 
        "id": "sg:person.0763326335.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763326335.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "From the Thoracic Oncology Section, National Institutes of Health, Bethesda, Maryland, USA", 
          "id": "http://www.grid.ac/institutes/grid.94365.3d", 
          "name": [
            "From the Thoracic Oncology Section, National Institutes of Health, Bethesda, Maryland, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Temeck", 
        "givenName": "Barbara K.", 
        "id": "sg:person.01306041342.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306041342.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "From the Thoracic Oncology Section, National Institutes of Health, Bethesda, Maryland, USA", 
          "id": "http://www.grid.ac/institutes/grid.94365.3d", 
          "name": [
            "From the Thoracic Oncology Section, National Institutes of Health, Bethesda, Maryland, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kranda", 
        "givenName": "Karen", 
        "id": "sg:person.01032321717.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032321717.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radiation Biology Section, National Institutes of Health, Bethesda, Maryland, USA", 
          "id": "http://www.grid.ac/institutes/grid.94365.3d", 
          "name": [
            "Radiation Biology Section, National Institutes of Health, Bethesda, Maryland, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thomas", 
        "givenName": "Gunther", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radiation Biology Section, National Institutes of Health, Bethesda, Maryland, USA", 
          "id": "http://www.grid.ac/institutes/grid.94365.3d", 
          "name": [
            "Radiation Biology Section, National Institutes of Health, Bethesda, Maryland, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Russo", 
        "givenName": "Angelo", 
        "id": "sg:person.01046205245.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046205245.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Cancer Institute, Biomedical Engineering and Instrumentation Program, National Center for Research Resources, National Institutes of Health, Bethesda, Maryland, USA", 
          "id": "http://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "National Cancer Institute, Biomedical Engineering and Instrumentation Program, National Center for Research Resources, National Institutes of Health, Bethesda, Maryland, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Smith", 
        "givenName": "Paul", 
        "id": "sg:person.014154611317.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014154611317.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Cancer Institute, Biomedical Engineering and Instrumentation Program, National Center for Research Resources, National Institutes of Health, Bethesda, Maryland, USA", 
          "id": "http://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "National Cancer Institute, Biomedical Engineering and Instrumentation Program, National Center for Research Resources, National Institutes of Health, Bethesda, Maryland, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Friauf", 
        "givenName": "Walt", 
        "id": "sg:person.015660165207.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015660165207.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Biostatistics and Data Management Section, National Institutes of Health, Bethesda, Maryland, USA", 
          "id": "http://www.grid.ac/institutes/grid.94365.3d", 
          "name": [
            "Biostatistics and Data Management Section, National Institutes of Health, Bethesda, Maryland, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Steinberg", 
        "givenName": "Seth M.", 
        "id": "sg:person.014210640617.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014210640617.24"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf02303538", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003120273", 
          "https://doi.org/10.1007/bf02303538"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02307026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018395434", 
          "https://doi.org/10.1007/bf02307026"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1991.474", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014661732", 
          "https://doi.org/10.1038/bjc.1991.474"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1997-12", 
    "datePublishedReg": "1997-12-01", 
    "description": "Background: Patients with malignant pleural mesothelioma (MPM) usually die of progressive local disease. This report describes the results of a Phase III trial comparing maximum debulking surgery and postoperative cisplatin, interferon \u03b1-2b, and tamoxifen (CIT) immunochemotherapy with and without intraoperative photodynamic therapy (PDT) to determine (1) whether such a multimodal approach can be performed with minimum morbidity and mortality in malignant pleural mesothelioma (MPM), and (2) whether first-generation (i.e., 630-nm laser light, Photofrin II) intrapleural PDT impacts on local recurrence or survival.Methods: From July 1993 to June 1996, 63 patients with localized MPM were randomized to either PDT or no PDT. The tumors of 15 patients could not be debulked to 5 mm. Patients assigned to PDT (n=25) and no PDT (n=23) were similar with respect to age, sex, tumor volume, and histology.Results: The type of resection (11 pleurectomies and 14 pneumonectomies vs. 12 pleurectomies and 11 pneumonectomies), length postoperative stay, and ICU time were comparable (PDT vs. no PDT). There was one operative death (hemorrhage), and each group had two bronchopleural fistulas. Postoperative staging divided patients into the following categories: stage I: PDT, 2, no PDT, 2; stage II: PDT, 2, no PDT, 2; stage III, PDT, 21; no PDT, 17; stage IV, PDT, 0; 0; no PDT, 2. Comparable numbers of CIT cycles were delivered. Median survival for the 15 non-debulked patients was 7.2 months, compared to 14 months for the 48 patients on protocol. There were no differences in median survival (14.4 vs. 14.1 months) or median progression-free time (8.5 vs. 7.7 months), and sites of first recurrence were similar.Conclusions: Aggressive multimodal therapy can be delivered for patients with higher stage MPM. First-generation PDT does not prolong survival or increase local control for MPM.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf02303746", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1105545", 
        "issn": [
          "1068-9265", 
          "1534-4681"
        ], 
        "name": "Annals of Surgical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "4"
      }
    ], 
    "keywords": [
      "malignant pleural mesothelioma", 
      "intraoperative photodynamic therapy", 
      "pleural mesothelioma", 
      "median survival", 
      "median progression-free time", 
      "progression-free time", 
      "progressive local disease", 
      "aggressive multimodal therapy", 
      "photodynamic therapy", 
      "phase III trials", 
      "type of resection", 
      "trial of surgery", 
      "intrapleural photodynamic therapy", 
      "postoperative cisplatin", 
      "ICU time", 
      "operative deaths", 
      "postoperative immunochemotherapy", 
      "postoperative stay", 
      "minimum morbidity", 
      "first recurrence", 
      "local recurrence", 
      "local disease", 
      "bronchopleural fistula", 
      "multimodal therapy", 
      "tumor volume", 
      "stage III", 
      "patients", 
      "stage I", 
      "stage IV", 
      "local control", 
      "interferon \u03b1-2b", 
      "stage II", 
      "mesothelioma", 
      "therapy", 
      "phase III", 
      "immunochemotherapy", 
      "survival", 
      "multimodal approach", 
      "surgery", 
      "recurrence", 
      "trials", 
      "months", 
      "comparable number", 
      "morbidity", 
      "resection", 
      "fistula", 
      "stay", 
      "tumors", 
      "\u03b1-2b", 
      "histology", 
      "mortality", 
      "disease", 
      "cisplatin", 
      "death", 
      "age", 
      "sex", 
      "report", 
      "group", 
      "control", 
      "differences", 
      "time", 
      "protocol", 
      "volume", 
      "categories", 
      "sites", 
      "number", 
      "types", 
      "results", 
      "cycle", 
      "respect", 
      "approach", 
      "III trial", 
      "tamoxifen (CIT) immunochemotherapy", 
      "first-generation (i.e., 630-nm laser light, Photofrin II) intrapleural PDT", 
      "length postoperative stay", 
      "CIT cycles", 
      "non-debulked patients", 
      "higher stage MPM", 
      "stage MPM", 
      "First-generation PDT"
    ], 
    "name": "Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma", 
    "pagination": "628-633", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1051247127"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf02303746"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "9416409"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf02303746", 
      "https://app.dimensions.ai/details/publication/pub.1051247127"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:09", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_302.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf02303746"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf02303746'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf02303746'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf02303746'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf02303746'


 

This table displays all metadata directly associated to this object as RDF triples.

285 TRIPLES      22 PREDICATES      129 URIs      118 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf02303746 schema:about N00e98204fbb240c5b3ccd26dd421bbb1
2 N12974f06ad1d4a70bfc7666740ea8f66
3 N1a9b78bc5f574e24a5db896bc4586da9
4 N252dd396988246389c069292a2932524
5 N32d13fc516e94aaf8076ca0c9599eaad
6 N569ff821015443bf9f62dd6c62367ca1
7 N689fde28cdb84dfaa65807265aa99b32
8 N7b756354408749b18c15c553b73290fa
9 N7f423dd236034877af15a0733756f87d
10 N93908d46fe844a8fac235898374d5608
11 Na25fb003585d46839ff536b1871a42c2
12 Nc4f567b1e8b8427fbc242162e74f3c48
13 Ncb3c3f70344a468c97afda1e0be159db
14 Ncdf21830c8cd45ba8c4a965b8a15bf25
15 Ndf92be1839f5429fb121a8de323d9466
16 Ne2e92f0e7948425fad2e83e951a54861
17 Ne3320e644ac14692afc2b0ed57719156
18 Nea517720d2724db4801990c45b3e42ae
19 Nf3abfb0cc76545ccb47d00c333e89a66
20 anzsrc-for:11
21 anzsrc-for:1112
22 schema:author N6144343959c14cfe82ffccd72ac1111e
23 schema:citation sg:pub.10.1007/bf02303538
24 sg:pub.10.1007/bf02307026
25 sg:pub.10.1038/bjc.1991.474
26 schema:datePublished 1997-12
27 schema:datePublishedReg 1997-12-01
28 schema:description Background: Patients with malignant pleural mesothelioma (MPM) usually die of progressive local disease. This report describes the results of a Phase III trial comparing maximum debulking surgery and postoperative cisplatin, interferon α-2b, and tamoxifen (CIT) immunochemotherapy with and without intraoperative photodynamic therapy (PDT) to determine (1) whether such a multimodal approach can be performed with minimum morbidity and mortality in malignant pleural mesothelioma (MPM), and (2) whether first-generation (i.e., 630-nm laser light, Photofrin II) intrapleural PDT impacts on local recurrence or survival.Methods: From July 1993 to June 1996, 63 patients with localized MPM were randomized to either PDT or no PDT. The tumors of 15 patients could not be debulked to 5 mm. Patients assigned to PDT (n=25) and no PDT (n=23) were similar with respect to age, sex, tumor volume, and histology.Results: The type of resection (11 pleurectomies and 14 pneumonectomies vs. 12 pleurectomies and 11 pneumonectomies), length postoperative stay, and ICU time were comparable (PDT vs. no PDT). There was one operative death (hemorrhage), and each group had two bronchopleural fistulas. Postoperative staging divided patients into the following categories: stage I: PDT, 2, no PDT, 2; stage II: PDT, 2, no PDT, 2; stage III, PDT, 21; no PDT, 17; stage IV, PDT, 0; 0; no PDT, 2. Comparable numbers of CIT cycles were delivered. Median survival for the 15 non-debulked patients was 7.2 months, compared to 14 months for the 48 patients on protocol. There were no differences in median survival (14.4 vs. 14.1 months) or median progression-free time (8.5 vs. 7.7 months), and sites of first recurrence were similar.Conclusions: Aggressive multimodal therapy can be delivered for patients with higher stage MPM. First-generation PDT does not prolong survival or increase local control for MPM.
29 schema:genre article
30 schema:inLanguage en
31 schema:isAccessibleForFree false
32 schema:isPartOf N09d8c5b34b1045ba8a3f2fdf9f50efb4
33 N81ec6a0a66084edb8e4fdafb0b3cecd4
34 sg:journal.1105545
35 schema:keywords CIT cycles
36 First-generation PDT
37 ICU time
38 III trial
39 age
40 aggressive multimodal therapy
41 approach
42 bronchopleural fistula
43 categories
44 cisplatin
45 comparable number
46 control
47 cycle
48 death
49 differences
50 disease
51 first recurrence
52 first-generation (i.e., 630-nm laser light, Photofrin II) intrapleural PDT
53 fistula
54 group
55 higher stage MPM
56 histology
57 immunochemotherapy
58 interferon α-2b
59 intraoperative photodynamic therapy
60 intrapleural photodynamic therapy
61 length postoperative stay
62 local control
63 local disease
64 local recurrence
65 malignant pleural mesothelioma
66 median progression-free time
67 median survival
68 mesothelioma
69 minimum morbidity
70 months
71 morbidity
72 mortality
73 multimodal approach
74 multimodal therapy
75 non-debulked patients
76 number
77 operative deaths
78 patients
79 phase III
80 phase III trials
81 photodynamic therapy
82 pleural mesothelioma
83 postoperative cisplatin
84 postoperative immunochemotherapy
85 postoperative stay
86 progression-free time
87 progressive local disease
88 protocol
89 recurrence
90 report
91 resection
92 respect
93 results
94 sex
95 sites
96 stage I
97 stage II
98 stage III
99 stage IV
100 stage MPM
101 stay
102 surgery
103 survival
104 tamoxifen (CIT) immunochemotherapy
105 therapy
106 time
107 trial of surgery
108 trials
109 tumor volume
110 tumors
111 type of resection
112 types
113 volume
114 α-2b
115 schema:name Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma
116 schema:pagination 628-633
117 schema:productId N74ef7fb57cb94475a5ab57c2a12b83eb
118 N7e1ea0f9a30d497eb11d7526fbe0e529
119 Ndc62cd99c658417ab23a24f7ae23bdb8
120 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051247127
121 https://doi.org/10.1007/bf02303746
122 schema:sdDatePublished 2022-01-01T18:09
123 schema:sdLicense https://scigraph.springernature.com/explorer/license/
124 schema:sdPublisher N0d382b4fc4534cd8ae2f40f025e16a9d
125 schema:url https://doi.org/10.1007/bf02303746
126 sgo:license sg:explorer/license/
127 sgo:sdDataset articles
128 rdf:type schema:ScholarlyArticle
129 N00e98204fbb240c5b3ccd26dd421bbb1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Female
131 rdf:type schema:DefinedTerm
132 N099ce94805b34471a07390e7cb95fb07 rdf:first sg:person.014210640617.24
133 rdf:rest rdf:nil
134 N09d8c5b34b1045ba8a3f2fdf9f50efb4 schema:issueNumber 8
135 rdf:type schema:PublicationIssue
136 N0d382b4fc4534cd8ae2f40f025e16a9d schema:name Springer Nature - SN SciGraph project
137 rdf:type schema:Organization
138 N12974f06ad1d4a70bfc7666740ea8f66 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Intraoperative Care
140 rdf:type schema:DefinedTerm
141 N1a9b78bc5f574e24a5db896bc4586da9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Humans
143 rdf:type schema:DefinedTerm
144 N252dd396988246389c069292a2932524 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Aged
146 rdf:type schema:DefinedTerm
147 N32d13fc516e94aaf8076ca0c9599eaad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Pleural Neoplasms
149 rdf:type schema:DefinedTerm
150 N3fc36ee2a2a74d0f8513174b39f7df93 rdf:first N7bb0137bef7544719fd6b739da850879
151 rdf:rest N6f22682d21124c599087efc77c63f249
152 N569ff821015443bf9f62dd6c62367ca1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Middle Aged
154 rdf:type schema:DefinedTerm
155 N575237df2bff4a6890af898c69368154 rdf:first sg:person.01306041342.14
156 rdf:rest N72bdb89968dd45c8b18f65ee4337984a
157 N6144343959c14cfe82ffccd72ac1111e rdf:first sg:person.0763326335.92
158 rdf:rest N575237df2bff4a6890af898c69368154
159 N689fde28cdb84dfaa65807265aa99b32 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Adult
161 rdf:type schema:DefinedTerm
162 N6f22682d21124c599087efc77c63f249 rdf:first sg:person.01046205245.21
163 rdf:rest Ncce0e3393a604beba3ce7642e33eeca3
164 N72bdb89968dd45c8b18f65ee4337984a rdf:first sg:person.01032321717.09
165 rdf:rest N3fc36ee2a2a74d0f8513174b39f7df93
166 N74ef7fb57cb94475a5ab57c2a12b83eb schema:name doi
167 schema:value 10.1007/bf02303746
168 rdf:type schema:PropertyValue
169 N7b756354408749b18c15c553b73290fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Survival Analysis
171 rdf:type schema:DefinedTerm
172 N7bb0137bef7544719fd6b739da850879 schema:affiliation grid-institutes:grid.94365.3d
173 schema:familyName Thomas
174 schema:givenName Gunther
175 rdf:type schema:Person
176 N7e1ea0f9a30d497eb11d7526fbe0e529 schema:name dimensions_id
177 schema:value pub.1051247127
178 rdf:type schema:PropertyValue
179 N7f423dd236034877af15a0733756f87d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Recombinant Proteins
181 rdf:type schema:DefinedTerm
182 N81ec6a0a66084edb8e4fdafb0b3cecd4 schema:volumeNumber 4
183 rdf:type schema:PublicationVolume
184 N93908d46fe844a8fac235898374d5608 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Antineoplastic Combined Chemotherapy Protocols
186 rdf:type schema:DefinedTerm
187 Na25fb003585d46839ff536b1871a42c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Tamoxifen
189 rdf:type schema:DefinedTerm
190 Nc4f567b1e8b8427fbc242162e74f3c48 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Mesothelioma
192 rdf:type schema:DefinedTerm
193 Ncb3c3f70344a468c97afda1e0be159db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Photochemotherapy
195 rdf:type schema:DefinedTerm
196 Ncce0e3393a604beba3ce7642e33eeca3 rdf:first sg:person.014154611317.32
197 rdf:rest Nd9b0bcc4973d4c0b8dc0602aed8c39b2
198 Ncdf21830c8cd45ba8c4a965b8a15bf25 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Cisplatin
200 rdf:type schema:DefinedTerm
201 Nd9b0bcc4973d4c0b8dc0602aed8c39b2 rdf:first sg:person.015660165207.76
202 rdf:rest N099ce94805b34471a07390e7cb95fb07
203 Ndc62cd99c658417ab23a24f7ae23bdb8 schema:name pubmed_id
204 schema:value 9416409
205 rdf:type schema:PropertyValue
206 Ndf92be1839f5429fb121a8de323d9466 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Interferon alpha-2
208 rdf:type schema:DefinedTerm
209 Ne2e92f0e7948425fad2e83e951a54861 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
210 schema:name Combined Modality Therapy
211 rdf:type schema:DefinedTerm
212 Ne3320e644ac14692afc2b0ed57719156 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Male
214 rdf:type schema:DefinedTerm
215 Nea517720d2724db4801990c45b3e42ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
216 schema:name Prospective Studies
217 rdf:type schema:DefinedTerm
218 Nf3abfb0cc76545ccb47d00c333e89a66 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
219 schema:name Interferon-alpha
220 rdf:type schema:DefinedTerm
221 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
222 schema:name Medical and Health Sciences
223 rdf:type schema:DefinedTerm
224 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
225 schema:name Oncology and Carcinogenesis
226 rdf:type schema:DefinedTerm
227 sg:journal.1105545 schema:issn 1068-9265
228 1534-4681
229 schema:name Annals of Surgical Oncology
230 schema:publisher Springer Nature
231 rdf:type schema:Periodical
232 sg:person.01032321717.09 schema:affiliation grid-institutes:grid.94365.3d
233 schema:familyName Kranda
234 schema:givenName Karen
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032321717.09
236 rdf:type schema:Person
237 sg:person.01046205245.21 schema:affiliation grid-institutes:grid.94365.3d
238 schema:familyName Russo
239 schema:givenName Angelo
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046205245.21
241 rdf:type schema:Person
242 sg:person.01306041342.14 schema:affiliation grid-institutes:grid.94365.3d
243 schema:familyName Temeck
244 schema:givenName Barbara K.
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306041342.14
246 rdf:type schema:Person
247 sg:person.014154611317.32 schema:affiliation grid-institutes:grid.48336.3a
248 schema:familyName Smith
249 schema:givenName Paul
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014154611317.32
251 rdf:type schema:Person
252 sg:person.014210640617.24 schema:affiliation grid-institutes:grid.94365.3d
253 schema:familyName Steinberg
254 schema:givenName Seth M.
255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014210640617.24
256 rdf:type schema:Person
257 sg:person.015660165207.76 schema:affiliation grid-institutes:grid.48336.3a
258 schema:familyName Friauf
259 schema:givenName Walt
260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015660165207.76
261 rdf:type schema:Person
262 sg:person.0763326335.92 schema:affiliation grid-institutes:grid.94365.3d
263 schema:familyName Pass
264 schema:givenName Harvey I.
265 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763326335.92
266 rdf:type schema:Person
267 sg:pub.10.1007/bf02303538 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003120273
268 https://doi.org/10.1007/bf02303538
269 rdf:type schema:CreativeWork
270 sg:pub.10.1007/bf02307026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018395434
271 https://doi.org/10.1007/bf02307026
272 rdf:type schema:CreativeWork
273 sg:pub.10.1038/bjc.1991.474 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014661732
274 https://doi.org/10.1038/bjc.1991.474
275 rdf:type schema:CreativeWork
276 grid-institutes:grid.48336.3a schema:alternateName National Cancer Institute, Biomedical Engineering and Instrumentation Program, National Center for Research Resources, National Institutes of Health, Bethesda, Maryland, USA
277 schema:name National Cancer Institute, Biomedical Engineering and Instrumentation Program, National Center for Research Resources, National Institutes of Health, Bethesda, Maryland, USA
278 rdf:type schema:Organization
279 grid-institutes:grid.94365.3d schema:alternateName Biostatistics and Data Management Section, National Institutes of Health, Bethesda, Maryland, USA
280 From the Thoracic Oncology Section, National Institutes of Health, Bethesda, Maryland, USA
281 Radiation Biology Section, National Institutes of Health, Bethesda, Maryland, USA
282 schema:name Biostatistics and Data Management Section, National Institutes of Health, Bethesda, Maryland, USA
283 From the Thoracic Oncology Section, National Institutes of Health, Bethesda, Maryland, USA
284 Radiation Biology Section, National Institutes of Health, Bethesda, Maryland, USA
285 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...